- Sublingual NAD+ is the new gold standard for daily NAD+
supplementation, without the need for precursors
SINGAPORE, Sept. 1,
2024 /PRNewswire/ -- iX Biopharma (the
"Company"), a specialty pharmaceutical company specializing
in drug delivery systems and a leader in innovative healthspan
nutraceuticals, has announced groundbreaking results from a
pharmacokinetic study evaluating the sublingual absorption of a
novel NAD+ wafer, SL-NAD+. This study is the first to provide
compelling evidence that NAD+ can directly enter cells, offering a
promising new approach to NAD+ supplementation.
The study consisted of 3 parts: 2 single-dose PK studies and a
multiple-dose PK study, conducted in 18 Sprague-Dawley rats,
examining the plasma and red blood cell NAD+ levels following
sublingual administration of NAD+. Assessment of NAD+ levels were
done via the LC-MS/MS method, one of the most advanced and reliable
methods to test for NAD+.
The results revealed several important findings:
- First evidence of direct cellular entry: The study
strongly suggests that NAD+ can be transported in and out of cells
directly (NAD+ flux), most probably via connexin 43 hemichannels
and other solute carrier channels. This is the first in-vivo study
to provide evidence supporting this capability.
- Rapid sublingual absorption: Mean peak plasma concentration, a
2-fold increase in plasma NAD+ levels, was achieved within 10
minutes of dosing. This underscores the effectiveness of
sublingual delivery through the mucosa.
- Significant bioavailability: The findings suggest a
sublingual bioavailability of SL-NAD+ at 22% compared to
intravenous (IV) administration. This provides a promising
alternative to IV NAD+ therapy, with the potential for more
convenient and sustained NAD+ delivery.
Dr. Janakan Krishnarajah, Chief Operating Officer and
Chief Medical Officer of iX Biopharma, said: "This study's findings
provide strong evidence that our innovative sublingual freeze-dried
technology delivers NAD+ rapidly into plasma and then directly into
cells, challenging the previously held belief that its large size
prevents cellular penetration. Along with the positive data from
our recent human clinical study, this breakthrough positions direct
NAD+ supplementation as the new gold standard for boosting NAD+
levels, removing the need for precursors."
About NAD+ and SL-NAD+
NAD (nicotinamide adenine dinucleotide) is a critical molecule
in our body responsible for vital cellular functions in the body.
It is crucial for energy production, cellular metabolism, DNA
repair, regulating sleep cycles and promoting healthy aging. NAD+
levels decrease as we age, with levels typically dropping to half
by the time we reach 50. The decline in NAD+ levels with age is
linked to various age-related health concerns and metabolic
disorders. In recent years, NAD+ has become an important focus in
scientific research on aging, with maintenance of adequate NAD+
levels being linked to healthy aging and longevity. Clinical trials
have also been conducted to investigate the potential of NAD+ in
treating various age-related diseases, such as Type 2 Diabetes,
Non-Alcoholic Fatty Liver Disease, neurodegenerative diseases like
Parkinson's disease, cardiovascular and skeletal muscle
diseases.
Despite its potential, NAD+ has been challenging to utilise
effectively, other than through IV. Alternative ways to boost NAD+
levels with NAD precursors, like NMN and NR, may be inefficient due
to bioavailability and other issues, such as inefficient conversion
to NAD+ due to age-related declines in enzyme activity.
SL-NAD+ is a novel sublingual wafer that delivers NAD+ directly
into the bloodstream, bypassing the digestive system to ensure
higher bioavailability and significantly boosting intracellular
NAD+ levels. The Company's proprietary freeze-drying
process and patented wafer formulation stabilises NAD+
and delivers them as nanoparticles, ensuring rapid disintegration,
release, and absorption through the sublingual mucosa. SL-NAD+ is
available for purchase on https://entity-health.com/product/sl-nad/
and through select specialist clinics in Singapore.
About iX Biopharma Ltd
iX Biopharma is a specialty pharmaceutical and nutraceutical
company listed on the Catalist board of the Singapore Exchange
Securities Trading Limited (SGX-ST), operating a fully integrated
business model from drug development to manufacturing and supply,
with facilities in Australia. The
Group is focused on the development and commercialisation of
pharmaceutical drugs and innovative nutraceuticals using novel,
patent-protected formulations for sublingual delivery.
iX Biopharma has developed a number of drug delivery platform
technologies, including WaferiX, WaferlogiX and NADiX, which
deliver small molecule and biologics sublingually via the mucosa
for better absorption, faster onset of action and predictable
effect. The drug delivery platforms are particularly useful for
drug repurposing, where existing approved drugs are developed into
new drugs targeting different indications or a different route of
administration, at a lower development cost and risk. iX
Biopharma's portfolio includes among others, ketamine,
dexmedetomidine, medicinal cannabis and nutraceuticals designed to
improve healthspan and longevity.
View original
content:https://www.prnewswire.com/news-releases/new-study-demonstrates-that-sl-nad-delivers-nad-into-cells-302235588.html
SOURCE iX Biopharma